Compare antipsychotic effects, distinguish motor syndromes, monitor mood stabilizers, and use benzodiazepines and buspirone with clear safety plans.
A patient who starts pacing after an antipsychotic dose increase may need less dopamine blockade, not more. A patient whose fine lithium tremor becomes coarse with ataxia needs a toxicity assessment, not routine reassurance. This lesson organizes drugs around the symptom they treat, the physiology they can disturb, and the finding that should change the plan.
Antipsychotic names predict patterns, not identical effects
Dopamine D2 antagonism is central to many antipsychotics. Reducing mesolimbic dopamine signaling can improve hallucinations and delusions, while effects in other pathways contribute to adverse reactions. Serotonin 5-HT2A antagonism is common among second-generation agents, but the class is not mechanistically uniform. Aripiprazole is a D2 and 5-HT1A partial agonist with 5-HT2A antagonism. It should not be described as a simple D2 blocker. [1][13]
Mesolimbic signaling
Reducing excessive signaling can lessen positive psychotic symptoms. Clinical response still depends on the illness and the individual.
Nigrostriatal signaling
D2 blockade can produce dystonia, parkinsonism, and akathisia. New motor symptoms can resemble psychiatric deterioration.
Tuberoinfundibular signaling
Dopamine normally inhibits pituitary prolactin release. Blocking this effect can cause galactorrhea, menstrual changes, and sexual dysfunction.
High-potency first-generation agents such as haloperidol and fluphenazine generally produce more extrapyramidal symptoms at therapeutic use than low-potency agents. Chlorpromazine and thioridazine have more prominent antimuscarinic, H1, and alpha-1 effects, with sedation, orthostasis, and dry mouth or retention. Potency describes dose needed for an effect, not superior clinical efficacy. Thioridazine has important QT and pigmentary retinal toxicity concerns, and its label reserves use for schizophrenia that has not responded adequately to other drugs. [19]
Antipsychotics also have selected non-schizophrenia roles, including acute mania and, for particular agents, tics, nausea, or intractable hiccups. These indications are agent-specific. Chlorpromazine has antiemetic and intractable-hiccup indications. IV haloperidol is used off-label in the US; the injection label states that this route is not approved and calls for ECG monitoring if it is used. [17][18] Antipsychotics are not general treatment for every form of distress.
Choose among second-generation agents using previous response and the adverse effects the patient can least afford. Olanzapine and clozapine have substantial metabolic liabilities. Quetiapine commonly causes sedation and orthostasis and has roles in acute bipolar mania and depression. The extended-release product also has an adjunctive MDD indication; this does not make it a routine insomnia drug. [20] Risperidone and its active metabolite paliperidone often increase prolactin; paliperidone requires attention to renal function.
Aripiprazole tends to have a lower metabolic burden than olanzapine but can cause akathisia and impulse-control problems. Ziprasidone requires food with oral dosing and has QT precautions. [2][13][14][15]
Second-generation status does not guarantee freedom from motor symptoms or reliable correction of cognitive and negative symptoms. Establish baseline weight, blood pressure, glycemic and lipid measures, relevant motor findings, and cardiac or endocrine risks, then reassess. A normal pretreatment measurement is the start of monitoring, not a lifetime exemption. [1]
Aripiprazole also has an adjunctive MDD indication. Quetiapine's US label recommends a lens examination at initiation or shortly afterward and every six months during chronic use; observed lens changes have not established causation. These are agent-specific indications and precautions. [13][20]
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 1
Show answer and explanations for case 1
A. Dopamine D2 activation stimulates prolactin release. (Why this does not fit)
Dopamine normally inhibits lactotroph secretion through D2 receptors; blocking that inhibition increases prolactin.
B. Selective H1 blockade releases prolactin by directly suppressing hypothalamic dopamine synthesis. (Why this does not fit)
H1 effects explain sedation and appetite changes, not this established D2-mediated endocrine effect.
C. Muscarinic blockade directly increases pituitary prolactin secretion. (Why this does not fit)
Antimuscarinic effects cause findings such as dry mouth and retention; they do not explain risperidone-associated hyperprolactinemia.
D. D2 blockade reduces dopamine's inhibition of pituitary prolactin release. (Best answer)
The tuberoinfundibular dopamine effect explains hyperprolactinemic symptoms with risperidone.
Takeaway: Dopamine blockade can produce endocrine as well as motor effects.
Typical contextHours to days, with sustained neck, jaw, eye, or laryngeal contractions
Treatment directionPrompt anticholinergic treatment and airway assessment if indicated
PatternAkathisia
Typical contextOften after starting or increasing treatment, with inner restlessness and inability to remain still
Treatment directionReview dose or agent; a beta blocker or selected alternative adjunct may help
PatternDrug-induced parkinsonism
Typical contextUsually develops over days to months, with rigidity, bradykinesia, and sometimes tremor
Treatment directionReview dose or agent; selected symptomatic treatment requires an adverse-effect assessment
PatternTardive dyskinesia
Typical contextUsually after sustained exposure, with involuntary oral, facial, limb, or truncal activity
Treatment directionAssess severity and psychiatric needs; consider a VMAT2 inhibitor for significant symptoms
These intervals are tendencies, not exclusion rules. The distress of akathisia is subjective as well as visible; ask how the patient feels rather than diagnosing anxiety from pacing alone. Acute dystonia can threaten breathing when the larynx is involved. Benztropine or diphenhydramine can help dystonia, but routine anticholinergic treatment is not the answer for tardive dyskinesia. It may worsen that syndrome. [1][2]
For parkinsonism, reducing the dose or selecting another antipsychotic may be preferable to adding chronic anticholinergic burden, especially in an older person with cognitive impairment or urinary retention. Symptoms can persist after the drug is withdrawn or expose underlying Parkinson disease. For tardive dyskinesia, use structured assessment and shared planning. Abrupt antipsychotic discontinuation may cause relapse and can transiently worsen dyskinesia. Valbenazine and deutetrabenazine are VMAT2 treatment options; the decision depends on functional impact and risks. [1]
Fever, diffuse rigidity, altered consciousness, and autonomic instability after dopamine blockade suggest neuroleptic malignant syndrome. Stop the suspected drug and arrange urgent supportive medical care, including evaluation for renal injury and other complications. Selected severe cases may receive specialist-directed bromocriptine or dantrolene. Do not confuse this systemic illness with an isolated neck spasm. Serotonin toxicity more often follows a serotonergic change and features clonus and hyperreflexia, although severe presentations can overlap. [2]
Route-specific hazards matter as much as syndrome recognition. IM olanzapine with a parenteral benzodiazepine is not recommended by the label because of excessive sedation and cardiorespiratory depression. A generic combination protocol does not erase that warning. Reassess ventilation and circulation after acute calming treatment.
Syncope with prolonged QT and polymorphic ventricular tachycardia suggests torsades de pointes. Stop contributing QT-prolonging drugs, correct electrolyte abnormalities and obtain urgent monitored care. AHA allows consideration of IV magnesium for recurrent long-QT polymorphic VT. Sustained polymorphic VT requires immediate unsynchronized shock. QT status matters: these drug recommendations differ from polymorphic VT with a normal QT. [15][22]
Clozapine requires an active monitoring relationship
Clozapine is recommended for treatment-resistant schizophrenia, commonly established after two adequate antipsychotic trials with adherence and diagnosis reviewed. It also has a separate indication for reducing recurrent suicidal behavior in schizophrenia or schizoaffective disorder in patients judged at chronic risk. It is not simply the next sedating drug to try for insomnia. [1][3]
The FDA removed the clozapine REMS program effective June 13, 2025. Enrollment and dispensing verification under that program are no longer required, but the severe-neutropenia risk and label-recommended ANC monitoring remain. Administrative deregistration is not evidence that blood monitoring has become unnecessary. [4]
Interpret the absolute neutrophil count using the applicable label pathway. The general baseline threshold is 1500/microliter, while patients with documented Duffy-null associated neutrophil count, termed benign ethnic neutropenia in parts of the label, have a separate threshold of 1000/microliter. Do not assign the alternate pathway merely from appearance or a racial category. Usual monitoring is weekly for six months, every two weeks for the next six months, and monthly thereafter when stable. A falling count changes the frequency and treatment plan. [3]
For a patient without the alternate pathway, ANC 500 to 999/microliter requires interruption and hematology input under the label. The documented alternate pathway can permit continuation at that range with hematology consultation and closer monitoring. Severe neutropenia below 500/microliter requires a different response; any later rechallenge is an individualized specialist risk-benefit decision, not a routine promise or a universally impossible option.
Ask about bowel function as deliberately as fever. Clozapine can cause severe gastrointestinal hypomotility, obstruction, and death; constipation is not automatically minor. Chest pain, dyspnea, persistent tachycardia, or fever early in treatment can indicate myocarditis. Other liabilities include seizures, orthostasis, hypersalivation, and metabolic disease. If treatment is interrupted, consult the restart instructions rather than resuming a high maintenance dose automatically, because cardiovascular collapse can occur with overly rapid re-exposure.
Fever requires assessment even when the most recent ANC was normal. The label directs interruption and a new ANC for temperature at least 38.5 C, with investigation of infection and other causes. Suspected myocarditis or cardiomyopathy requires stopping clozapine and urgent cardiac evaluation, rather than treating tachycardia as routine titration discomfort. [3]
Lithium follows kidney and sodium physiology
Lithium is used for acute mania and maintenance. Its cellular actions include effects on inositol signaling and glycogen synthase kinase pathways, but no single proposed mechanism fully explains clinical benefit. It is not hepatically metabolized or substantially protein-bound. Renal clearance makes changes in fluid balance, sodium handling, and interacting medication clinically important. [6][24]
Measure concentrations at a consistent trough time, generally 12 hours after the last dose. Acute treatment often targets roughly 0.8 to 1.2 mEq/L under the product label; maintenance targets are individualized, with NICE commonly starting at 0.6 to 0.8 mmol/L and considering higher targets for specified clinical reasons. For lithium, mEq/L and mmol/L are numerically equivalent. Do not interpret a level drawn shortly after a dose as if it were a trough. [5][6]
Before and during treatment, assess renal function, thyroid function, calcium, relevant electrolytes, weight, pregnancy considerations, and ECG indications. Recheck levels after dose changes, interacting drugs, or illnesses that alter fluid balance. Dehydration, thiazides, NSAIDs, and ACE inhibitors or ARBs can increase lithium exposure. Patients need a concrete plan for vomiting, diarrhea, fever, and medication changes.
A mild fine tremor can occur during otherwise effective treatment. New coarse tremor, ataxia, dysarthria, confusion, or substantial gastrointestinal symptoms require urgent toxicity assessment. Hold lithium when toxicity is suspected and assess the patient, concentration, kidney function, electrolytes, and hydration. Severe neurologic or renal toxicity may require dialysis assessment. A concentration in a customary range does not override concerning clinical findings.
Polyuria can reflect impaired renal response to vasopressin, producing nephrogenic diabetes insipidus. Check fluid balance and sodium rather than assuming thirst is psychiatric. Amiloride may be used in appropriate lithium-related polyuria management. Hypothyroidism, hyperparathyroidism or hypercalcemia, and chronic kidney effects also need follow-up. Benign leukocytosis and some ECG changes should not be confused with neutropenia, but new cardiac symptoms still require evaluation.
Pregnancy counseling should address the increased risk of cardiac malformations, including Ebstein anomaly, without portraying the absolute risk as inevitable or treating lithium as categorically forbidden in every pregnancy. Balance illness recurrence, alternatives, fetal assessment, and changing lithium clearance through pregnancy and the postpartum period. Persistent neurologic deficits after lithium toxicity are a distinct complication and should not be confused with ordinary reversible adverse effects. [6]
Lithium's mood-stabilizing role should not be presented as guaranteed suicide prevention. The 2024 VA/DoD guideline found insufficient evidence to recommend for or against lithium specifically to reduce suicide or attempts in mood disorders. Discuss the uncertainty and maintain an individualized safety and follow-up plan. [23]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 18
Show answer and explanations for case 18
A. Check only liver enzymes after the change. (Why this does not fit)
Lithium is not hepatically metabolized, so this misses the relevant risk.
B. Make no follow-up plan if the lithium dose itself is unchanged. (Why this does not fit)
An interacting drug can change exposure without a lithium dose change.
C. Review the interaction and arrange a coordinated alternative or lithium adjustment with close level monitoring. (Best answer)
Thiazides can increase lithium exposure through altered renal sodium handling.
D. Assume thiazides lower lithium levels because they increase urine output. (Why this does not fit)
More urine does not imply greater lithium clearance; the interaction often raises the level.
Takeaway: Changes in renal sodium handling can alter lithium concentration.
Valproate has antimanic, antiseizure, and migraine-prevention roles. Its effects involve GABA-related signaling and voltage-gated ion channels; the complete therapeutic mechanism is not settled. It is used in selected bipolar maintenance plans, but formulation and indication should be checked rather than assuming every use has the same US approval. Monitor liver function and blood counts with platelets, and ask about abdominal pain, vomiting, bruising, sedation, and reproductive plans. [7][5]
Valproate can cause severe hepatotoxicity, pancreatitis, thrombocytopenia, and hyperammonemic encephalopathy. New lethargy or confusion warrants an ammonia assessment when clinically indicated even if transaminases are normal. Weight gain, alopecia, tremor, and menstrual or hyperandrogenic problems also matter. Pregnancy exposure can cause neural tube defects and adverse neurodevelopment; folate does not make the exposure safe. For bipolar illness in pregnancy or people who may become pregnant, use is restricted to circumstances in which alternatives fail or are unacceptable under the relevant label and local requirements. [7]
Lamotrigine is FDA-approved for bipolar I maintenance, not for treating acute mania or an acute mood episode under that indication. Clinical guidelines also give it a role in bipolar depression. Distinguish guideline-supported practice from the precise approval. Slow titration makes it unsuitable as immediate control of a dangerous manic episode. [8][5]
Serious rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis, is a major lamotrigine hazard. Stop at the first sign of rash unless it is clearly unrelated and arrange appropriate assessment, especially for mucosal lesions, fever, or skin pain. Excessive starting doses, rapid escalation, and valproate coadministration increase risk. Valproate inhibits lamotrigine glucuronidation and reduces clearance; this is more precise than calling it a universal CYP interaction.
For adults with bipolar disorder taking valproate, the label starts lamotrigine at 25 mg every other day for the first two weeks. Without valproate or specified enzyme-inducing drugs, the corresponding initial regimen is 25 mg daily. Other interacting drugs require their own schedule. After an interruption exceeding five half-lives, return to initial titration guidance; half-life depends on the accompanying drugs. Estrogen-containing contraceptives can lower lamotrigine concentrations, and stopping them can raise concentrations. Do not improvise a fixed restart or interaction rule. [8]
Lamotrigine also has approved epilepsy indications. Its proposed antiseizure mechanism involves voltage-sensitive sodium channels and reduced excitatory transmitter release, although the clinical relevance of individual experimental effects remains uncertain. Dizziness, diplopia, ataxia and headache also deserve review. Its rash warning does not imply that other drugs cannot cause serious skin reactions. [8]
Separate immediate GABA effects from ongoing anxiety treatment
Benzodiazepines positively modulate GABA-A receptors and, in the conventional teaching model, increase the frequency of GABA-mediated chloride-channel opening. Barbiturates are classically contrasted by increased opening duration. Benzodiazepines can rapidly reduce anxiety and provide sedation, amnesia, muscle relaxation, and anticonvulsant effects. Their uses include selected acute anxiety crises, seizures, alcohol withdrawal, and procedures; they do not constitute a durable default treatment for every anxiety disorder. [10][16][25]
Diazepam and chlordiazepoxide have long-lived active metabolites. Lorazepam, oxazepam, and temazepam rely principally on glucuronidation without clinically important active metabolites and may be preferable when oxidative hepatic metabolism is impaired. They are not automatically safe in advanced liver disease or all uniformly short-acting. Clonazepam has a long parent-drug half-life; its metabolites are described as inactive or weakly active. [21] Midazolam's procedural amnesia is useful only with appropriate respiratory observation.
Alcohol, opioids, and other sedatives can compound respiratory depression. Falls, impaired driving, cognitive effects, and paradoxical disinhibition also matter. Physical dependence can occur during prescribed treatment and is not synonymous with a substance use disorder. Abrupt cessation can cause severe withdrawal and seizures. The 2025 joint tapering guideline supports individualized reductions, commonly beginning around 5 to 10 percent every two to four weeks and slowing or pausing according to response, rather than a fixed rapid schedule for everyone. [9][10]
Flumazenil can reverse benzodiazepine effects in selected circumstances, such as isolated iatrogenic oversedation in a nondependent patient. It is not routine treatment for an unknown overdose. Chronic benzodiazepine exposure, seizure treatment dependence, and serious cyclic antidepressant co-ingestion can make it dangerous. Support ventilation first, and continue observation because resedation may follow reversal. [11]
Buspirone acts mainly through 5-HT1A mechanisms and is used on a scheduled basis for persistent anxiety, with benefit developing over weeks. It does not provide an immediate rescue and does not substitute for the GABA effect needed to prevent benzodiazepine withdrawal. It is generally less sedating and lacks the usual benzodiazepine dependence profile, but dizziness, nausea, and individual impairment can occur. Review serotonergic and MAOI interactions rather than calling it interaction-free. [12]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 31
Show answer and explanations for case 31
A. Assume one dose prevents all later sedation. (Why this does not fit)
Resedation can occur after the antagonist effect diminishes.
B. Prioritize supportive resuscitation and avoid routine flumazenil because of seizure risk. (Best answer)
Chronic dependence and possible cyclic antidepressant poisoning make reversal hazardous.
C. Give flumazenil automatically for every suspected benzodiazepine exposure, including mixed overdoses and chronic daily use. (Why this does not fit)
It is not a universal antidote for mixed or uncertain overdoses.
D. Use flumazenil as a substitute for airway assessment. (Why this does not fit)
Reversal does not replace ventilation support or other resuscitation.
Takeaway: An antidote can be dangerous when the exposure and dependence history are unfavorable.
These original educational cases emphasize the finding that changes treatment. Each has one best answer; distinguish routine follow-up from a medication emergency.
Case 2
Show answer and explanations for case 2
A. Chlorpromazine cannot treat psychosis because its dose is larger. (Why this does not fit)
A larger therapeutic dose does not imply lack of antipsychotic efficacy.
B. The two drugs have identical receptor and tolerability profiles. (Why this does not fit)
Their differing anticholinergic, sedating, orthostatic, and motor effects matter clinically.
C. Haloperidol is a higher-potency drug; potency does not establish superior efficacy. (Best answer)
The dose scale reflects potency, while clinical response and adverse effects require separate comparison.
D. A lower milligram dose guarantees fewer extrapyramidal effects. (Why this does not fit)
High-potency first-generation drugs can have substantial motor adverse effects despite small milligram numbers.
Takeaway: Compare drugs by effect and risk, not by raw milligram size.
A. Increase dopamine blockade because slowness proves persistent psychosis. (Why this does not fit)
The physical findings are compatible with a medication adverse effect, not evidence of undertreated delusions.
B. Review whether the dose can be reduced or the agent changed before adding anticholinergic burden. (Best answer)
The motor syndrome may be drug-induced, while anticholinergics can worsen this patient's cognition and retention.
C. Automatically add indefinite high-dose benztropine without review. (Why this does not fit)
That adds predictable harms in the specific patient described.
D. Diagnose permanent Parkinson disease solely from the medication-associated timing, despite the recent antipsychotic exposure. (Why this does not fit)
Drug-induced parkinsonism is a major alternative, although persistent symptoms may later require further evaluation.
Takeaway: The treatment of an adverse effect can create another adverse effect.
A. A VMAT2 inhibitor such as valbenazine or deutetrabenazine. (Best answer)
These agents address clinically important tardive dyskinesia while the psychiatric regimen is reviewed.
B. Routine benztropine escalation. (Why this does not fit)
Anticholinergics are useful for some acute motor syndromes but are not routine TD treatment and may worsen it.
C. Increase haloperidol to suppress the dyskinesia as the continuing treatment strategy. (Why this does not fit)
More dopamine blockade can temporarily mask TD but adds exposure and does not provide an appropriate durable treatment strategy.
D. Amantadine as the preferred first pharmacologic treatment for disabling TD. (Why this does not fit)
Amantadine is an option for drug-induced parkinsonism and has more limited TD evidence; APA recommends VMAT2 treatment for moderate, severe or disabling antipsychotic-associated TD.
Takeaway: Match the motor syndrome to its treatment rather than treating all motor effects alike.
A. Switch to a third nonclozapine antipsychotic without discussing clozapine. (Why this does not fit)
With two adequate adherent trials and persistent symptoms, treatment resistance warrants a clozapine discussion rather than another routine trial alone.
B. Combine the two previously ineffective antipsychotics as the standard next step. (Why this does not fit)
Routine nonclozapine polypharmacy has added adverse effects and should not displace guideline-supported clozapine for established resistance.
C. Clozapine. (Best answer)
After confirmed adequate trials, clozapine is the recommended treatment for resistant schizophrenia, with eligibility and monitoring reviewed.
D. Continue the second failed regimen unchanged for another year. (Why this does not fit)
An adequate unsuccessful trial has already occurred; delaying reassessment prolongs uncontrolled illness.
Takeaway: Confirm trial adequacy before identifying treatment resistance and its next treatment.
A. Use the general pathway without considering the documented baseline condition. (Why this does not fit)
That ignores a specific label distinction intended for this context.
B. Continue treatment with unchanged monthly ANC monitoring. (Why this does not fit)
The alternate pathway can permit continuation at this count but calls for closer monitoring and hematology input.
C. Reduce clozapine by half and check the ANC only at the next routine monthly visit. (Why this does not fit)
For documented Duffy-null associated neutrophil count at 850/microliter, the label permits continuation with hematology consultation and increased monitoring, not a generic half-dose and routine monthly check.
D. The alternate pathway can permit continued treatment with hematology consultation and closer ANC monitoring. (Best answer)
At this range, the documented alternate pathway differs from the general interruption pathway.
Takeaway: The same numerical ANC can require a different action under a documented alternate pathway.
A. Reassure the patient that coarse tremor, unsteady gait, and confusion during gastroenteritis are benign lithium effects that do not require toxicity assessment. (Why this does not fit)
Coarse tremor with ataxia and confusion differs from an isolated mild fine tremor.
B. Increase lithium because confusion indicates mania. (Why this does not fit)
The illness and neurologic pattern favor toxicity until assessed.
C. Wait for a routine laboratory appointment several weeks later. (Why this does not fit)
The current neurologic abnormalities require urgent evaluation.
D. Hold lithium and arrange urgent toxicity assessment, including renal function, electrolytes, and a concentration. (Best answer)
Volume depletion can reduce lithium clearance, and the new neurologic findings are concerning.
Takeaway: Illness-related dehydration can turn a stable lithium regimen into toxicity.
A. Primary polydipsia from excessive water intake. (Why this does not fit)
This can cause dilute urine, but lithium exposure makes impaired renal concentration a specific concern; sodium, osmolality and fluid assessment distinguish the causes.
B. Reduced renal responsiveness to vasopressin causing nephrogenic diabetes insipidus. (Best answer)
Lithium can impair urinary concentration, requiring assessment of sodium, fluid balance, and treatment.
C. Central diabetes insipidus from deficient pituitary vasopressin release caused by lithium exposure at the hypothalamic-pituitary axis. (Why this does not fit)
Central deficiency also causes dilute polyuria, but lithium classically acts at the kidney rather than by eliminating pituitary vasopressin release.
D. Hyperglycemia-mediated osmotic diuresis. (Why this does not fit)
Osmotic diuresis from glucose is not supported by the normal glucose in this stem.
Takeaway: Do not label lithium-associated thirst and polyuria as purely behavioral.
A. Lithium-associated thyroid dysfunction should be evaluated and treated within an individualized maintenance plan. (Best answer)
The adverse effect requires care but does not automatically dictate abrupt loss of an effective mood treatment.
B. Treat the fatigue and cold intolerance as a depressive relapse and increase lithium before reviewing the elevated TSH or thyroid status. (Why this does not fit)
The raised TSH and cold intolerance require thyroid assessment rather than assuming residual mood symptoms.
C. Stop lithium abruptly as the only way to manage the thyroid abnormality. (Why this does not fit)
Hypothyroidism can often be treated while an effective lithium regimen continues, based on individual review.
D. Increase lithium to treat the fatigue before reviewing thyroid status. (Why this does not fit)
That does not address the identified endocrine abnormality.
Takeaway: Lithium follow-up includes endocrine function, not only serum drug levels.
A. Continue treatment without fetal-risk counseling because the patient has been stable. (Why this does not fit)
Stability supports considering continuation but does not remove the need for risk discussion and pregnancy monitoring.
B. Keep the same lithium dose and monitoring schedule throughout pregnancy, delivery, and postpartum despite expected renal and volume changes. (Why this does not fit)
Lithium clearance and volume status can change during pregnancy and postpartum; a specific monitoring plan is needed.
C. Abruptly stop the drug without discussing relapse or follow-up. (Why this does not fit)
An unplanned cessation can destabilize illness and does not provide a complete pregnancy plan.
D. Discuss cardiac malformation risk, relapse risk, alternatives, and a specialist monitoring plan. (Best answer)
The decision requires a balanced assessment rather than a guarantee of safety or an automatic prohibition.
Takeaway: Reproductive planning requires both fetal-risk counseling and illness-management planning.
A. Use the serum valproate concentration as the only toxicity investigation and do not check ammonia. (Why this does not fit)
A drug concentration is useful but does not replace ammonia testing when encephalopathy is suspected; hyperammonemia need not track the total concentration.
B. Repeat transaminases next month before investigating a medication cause. (Why this does not fit)
New confusion and lethargy require prompt assessment; hyperammonemia can occur with normal transaminases.
C. Check ammonia when evaluating possible valproate-associated encephalopathy. (Best answer)
Hyperammonemia can occur despite normal liver transaminases.
D. Exclude medication toxicity because transaminases are normal. (Why this does not fit)
Normal enzymes do not rule out hyperammonemic encephalopathy.
Takeaway: Normal liver enzymes do not exclude valproate-related hyperammonemia.
A. Review the interruption and interacting drugs and restart according to initial titration guidance when indicated. (Best answer)
After more than five half-lives, the label directs return to initial dosing guidance; the gap described is substantial.
B. Resume the full previous maintenance dose immediately because prior tolerance permanently prevents a serious lamotrigine rash after interruption. (Why this does not fit)
Prior tolerance does not remove the risk associated with an excessive restart dose.
C. Double the prior dose to replace missed tablets. (Why this does not fit)
Missed treatment is not corrected with a catch-up dose.
D. Use one universal three-day restart cutoff regardless of other medications. (Why this does not fit)
Lamotrigine half-life depends on interacting drugs, so the label uses a pharmacokinetic principle.
Takeaway: Restarting after a long interruption is a new dosing decision.
A. Use a fixed two-day taper for all patients. (Why this does not fit)
A uniform rapid schedule disregards duration, dose, withdrawal history, and response.
B. Replace the benzodiazepine with buspirone immediately and assume this fully prevents withdrawal symptoms and seizures during the transition. (Why this does not fit)
Buspirone lacks benzodiazepine cross-tolerance and does not prevent its withdrawal syndrome.
C. Agree on an individualized gradual taper, often starting with small reductions and adjusting to symptoms. (Best answer)
Long-term use can produce physical dependence, so fall risk should be addressed without provoking abrupt withdrawal.
D. Stop abruptly because the medication was prescribed rather than obtained illicitly. (Why this does not fit)
Physical dependence can develop during prescribed treatment, making abrupt cessation hazardous.
Takeaway: Reduce benzodiazepine risk with a patient-specific taper rather than sudden cessation.
A. Give IV magnesium, stop contributing QT-prolonging medication and correct electrolytes under continuous monitoring. (Best answer)
Recurrent polymorphic VT with prolonged QT is torsades. Magnesium may be considered, alongside correction of potassium and medication causes. Sustained polymorphic VT would require immediate unsynchronized shock.
B. Give amiodarone as the preferred prophylaxis for this long-QT rhythm. (Why this does not fit)
Amiodarone can prolong QT. Its role in recurrent normal-QT polymorphic VT does not transfer to torsades.
C. Give adenosine to terminate the recurrent ventricular rhythm. (Why this does not fit)
Adenosine is used for selected regular tachycardias; this is polymorphic ventricular tachycardia in a long-QT setting.
D. Continue ziprasidone and give a beta blocker to slow the sinus rate while awaiting outpatient review. (Why this does not fit)
This acquired long-QT ventricular arrhythmia needs urgent monitored correction. Further bradycardia may worsen pause-dependent torsades, and continued culprit exposure is inappropriate.
Takeaway: Treat the long-QT substrate and distinguish recurrent self-terminating torsades from sustained polymorphic VT requiring immediate shock.
